Market Research Logo

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Summary


Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, withsymptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 61 products in development for this indication, by 40 companies and five academic institutions. Key companies operating in this pipeline space include NLS Pharma Group and Shire.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. There are a total of 191 products in development for this indication, by 112 companies and 20 academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Sumitomo Dainippon Pharma, Luye Pharma Group, Otsuka Holdings and Vanderbilt University.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. There are a total of 134 products in development for this indication, by 85 companies and nine academic institutions. Key companies operating in this pipeline space include Omeros Corp, Suven Life Sciences, Heptares Therapeutics, Merck & Co, Sumitomo Dainippon Pharma and Vanderbilt University.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. There are a total of 11 products in development for this indication, by nine companies and one academic institution. Key companies operating in this pipeline space include Catalyst Pharmaceuticals, who are fielding two pipeline products.

Across all four of these indications, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

The report Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017, provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Neuropsychiatric Disorder Cluster Report Coverage
    • Attention Deficit Hyperactivity Disorder (ADHD) –Overview
    • Depression – Overview
    • Schizophrenia – Overview
    • Tourette Syndrome – Overview
  • Therapeutics Development
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 1: Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 2: Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 3: Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder
      • Table Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder
      • Table Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
      • Table Figure 4: Number of Products under Development for Depression
      • Table Number of Products under Development for Depression
      • Table Figure 5: Number of Products under Development by Companies, Depression
      • Table Number of Products under Development by Companies, Depression
      • Table Figure 6: Number of Products under Development by Universities/Institutes, Depression
      • Table Number of Products under Development by Universities/Institutes, Depression
      • Table Products under Development by Companies, Depression
      • Table Products under Development by Universities/Institutes, Depression
    • Schizophrenia
      • Table Figure 7: Number of Products under Development for Schizophrenia
      • Table Number of Products under Development for Schizophrenia
      • Table Figure 8: Number of Products under Development by Companies, Schizophrenia
      • Table Number of Products under Development by Companies, Schizophrenia
      • Table Figure 9: Number of Products under Development by Universities/Institutes, Schizophrenia
      • Table Number of Products under Development by Universities/Institutes, Schizophrenia
      • Table Products under Development by Companies, Schizophrenia
      • Table Products under Development by Universities/Institutes, Schizophrenia
    • Tourette Syndrome
      • Table Figure 10: Number of Products under Development for Tourette Syndrome
      • Table Number of Products under Development for Tourette Syndrome
      • Table Figure 11: Number of Products under Development by Companies, Tourette Syndrome
      • Table Number of Products under Development by Companies, Tourette Syndrome
      • Table Number of Products under Development by Universities/Institutes, Tourette Syndrome
      • Table Products under Development by Companies, Tourette Syndrome
      • Table Products under Development by Universities/Institutes, Tourette Syndrome
  • Therapeutics Assessment
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 12: Number of Products by Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 13: Number of Products by Stage and Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Number of Products by Stage and Target, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 14: Number of Products by Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder
      • Table Number of Products by Stage and Mechanism of Action, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 16: Number of Products by Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 17: Number of Products by Stage and Routes of Administration, Attention Deficit Hyperactivity Disorder
      • Table Number of Products by Stage and Route of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 18: Number of Products by Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Figure 19: Number of Products by Stage and Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Number of Products by Stage and Molecule Type, Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
      • Table Figure 20: Number of Products by Top 10 Targets, Depression
      • Table Figure 21: Number of Products by Stage and Top 10 Targets, Depression
      • Table Number of Products by Stage and Target, Depression
      • Table Figure 22: Number of Products by Top 10 Mechanism of Actions, Depression
      • Table Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Depression
      • Table Number of Products by Stage and Mechanism of Action, Depression
      • Table Figure 24: Number of Products by Top 10 Routes of Administration, Depression
      • Table Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Depression
      • Table Number of Products by Stage and Route of Administration, Depression
      • Table Figure 26: Number of Products by Molecule Types, Depression
      • Table Figure 27: Number of Products by Stage and Molecule Types, Depression
      • Table Number of Products by Stage and Molecule Type, Depression
    • Schizophrenia
      • Table Figure 28: Number of Products by Top 10 Targets, Schizophrenia
      • Table Figure 29: Number of Products by Stage and Top 10 Targets, Schizophrenia
      • Table Number of Products by Stage and Target, Schizophrenia
      • Table Figure 30: Number of Products by Top 10 Mechanism of Actions, Schizophrenia
      • Table Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Schizophrenia
      • Table Number of Products by Stage and Mechanism of Action, Schizophrenia
      • Table Figure 32: Number of Products by Routes of Administration, Schizophrenia
      • Table Figure 33: Number of Products by Stage and Routes of Administration, Schizophrenia
      • Table Number of Products by Stage and Route of Administration, Schizophrenia
      • Table Figure 34: Number of Products by Molecule Types, Schizophrenia
      • Table Figure 35: Number of Products by Stage and Molecule Types, Schizophrenia
      • Table Number of Products by Stage and Molecule Type, Schizophrenia
    • Tourette Syndrome
      • Table Figure 36: Number of Products by Top 10 Targets, Tourette Syndrome
      • Table Figure 37: Number of Products by Stage and Top 10 Targets, Tourette Syndrome
      • Table Number of Products by Stage and Target, Tourette Syndrome
      • Table Figure 38: Number of Products by Top 10 Mechanism of Actions, Tourette Syndrome
      • Table Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Tourette Syndrome
      • Table Number of Products by Stage and Mechanism of Action, Tourette Syndrome
      • Table Figure 40: Number of Products by Top 10 Routes of Administration, Tourette Syndrome
      • Table Figure 41: Number of Products by Stage and Routes of Administration, Tourette Syndrome
      • Table Number of Products by Stage and Route of Administration, Tourette Syndrome
      • Table Figure 42: Number of Products by Stage and Molecule Types, Tourette Syndrome
      • Table Number of Products by Stage and Molecule Type, Tourette Syndrome
  • Companies Involved in Therapeutics Development
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Aevi Genomic Medicine Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Alcobra Ltd
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Amarantus Bioscience Holdings Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by APeT Holding BV
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Arbor Pharmaceuticals LLC
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by BCWorld Pharm Co Ltd
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by BioHealthonomics Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by BioLite Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Cingulate Therapeutics LLC
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Collegium Pharmaceutical Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Curemark LLC
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by DURECT Corp
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Eli Lilly and Company
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Ensysce Biosciences Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by H. Lundbeck A/S
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Heptares Therapeutics Ltd
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Highland Therapeutics Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Integrative Research Laboratories Sweden AB
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by INVENT Pharmaceuticals Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by KemPharm Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Luc Therapeutics Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Merck & Co Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Neos Therapeutics Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by NeuroDerm Ltd
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Neurovance Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by NLS Pharma Group
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Noven Pharmaceuticals Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by P2D Bioscience
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Reviva Pharmaceuticals Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Shire Plc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by SK Biopharmaceuticals Co Ltd
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Sunovion Pharmaceuticals Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Supernus Pharmaceuticals Inc
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by Taisho Pharmaceutical Co Ltd
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Pipeline by TRImaran Pharma Inc
    • Depression
      • Table Depression – Pipeline by 4D Pharma PLC
      • Table Depression – Pipeline by AB Science SA
      • Table Depression – Pipeline by Acadia Pharmaceuticals Inc
      • Table Depression – Pipeline by Adamed Sp z oo
      • Table Depression – Pipeline by Addex Therapeutics Ltd
      • Table Depression – Pipeline by Aequus Pharmaceuticals Inc
      • Table Depression – Pipeline by Alkermes Plc
      • Table Depression – Pipeline by Allergan Plc
      • Table Depression – Pipeline by Alvogen Korea Co Ltd
      • Table Depression – Pipeline by Amorsa Therapeutics Inc
      • Table Depression – Pipeline by Anavex Life Sciences Corp
      • Table Depression – Pipeline by Angelini Group
      • Table Depression – Pipeline by Angita BV
      • Table Depression – Pipeline by Araim Pharmaceuticals Inc
      • Table Depression – Pipeline by AstraZeneca Plc
      • Table Depression – Pipeline by Avanir Pharmaceuticals Inc
      • Table Depression – Pipeline by Axsome Therapeutics Inc
      • Table Depression – Pipeline by Azevan Pharmaceuticals Inc
      • Table Depression – Pipeline by BioCrea GmbH
      • Table Depression – Pipeline by BioLite Inc
      • Table Depression – Pipeline by Bionomics Ltd
      • Table Depression – Pipeline by Boehringer Ingelheim GmbH
      • Table Depression – Pipeline by Bristol-Myers Squibb Company
      • Table Depression – Pipeline by Calico LLC
      • Table Depression – Pipeline by Celgene Corp
      • Table Depression – Pipeline by Celon Pharma SA
      • Table Depression – Pipeline by Cerecor Inc
      • Table Depression – Pipeline by Clera Inc
      • Table Depression – Pipeline by Delpor Inc
      • Table Depression – Pipeline by Domain Therapeutics SA
      • Table Depression – Pipeline by Eisai Co Ltd
      • Table Depression – Pipeline by Eli Lilly and Company
      • Table Depression – Pipeline by Evotec AG
      • Table Depression – Pipeline by F. Hoffmann-La Roche Ltd
      • Table Depression – Pipeline by Fabre-Kramer Pharmaceuticals Inc
      • Table Depression – Pipeline by FPRT Bio Inc
      • Table Depression – Pipeline by GlaxoSmithKline Plc
      • Table Depression – Pipeline by GliaCure Inc
      • Table Depression – Pipeline by H. Lundbeck A/S
      • Table Depression – Pipeline by Heptares Therapeutics Ltd
      • Table Depression – Pipeline by Hua Medicine (Shanghai) Ltd
      • Table Depression – Pipeline by Hyundai Pharmaceutical Co Ltd
      • Table Depression – Pipeline by Impel NeuroPharma Inc
      • Table Depression – Pipeline by INSYS Therapeutics Inc
      • Table Depression – Pipeline by Intas Pharmaceuticals Ltd
      • Table Depression – Pipeline by Intra-Cellular Therapies Inc
      • Table Depression – Pipeline by INVENT Pharmaceuticals Inc
      • Table Depression – Pipeline by Johnson & Johnson
      • Table Depression – Pipeline by KemPharm Inc
      • Table Depression – Pipeline by Lead Discovery Center GmbH
      • Table Depression – Pipeline by Les Laboratoires Servier SAS
      • Table Depression – Pipeline by Lixte Biotechnology Holdings Inc
      • Table Depression – Pipeline by Luye Pharma Group Ltd
      • Table Depression – Pipeline by Mapi Pharma Ltd
      • Table Depression – Pipeline by Mapreg SAS
      • Table Depression – Pipeline by Medlab Clinical Ltd
      • Table Depression – Pipeline by Meta-IQ ApS
      • Table Depression – Pipeline by Methylation Sciences Inc
      • Table Depression – Pipeline by miCure Therapeutics Ltd
      • Table Depression – Pipeline by Mitsubishi Tanabe Pharma Corp
      • Table Depression – Pipeline by Navya Biologicals Pvt Ltd
      • Table Depression – Pipeline by Neuralstem Inc
      • Table Depression – Pipeline by Neurocrine Biosciences Inc
      • Table Depression – Pipeline by NeuroNascent Inc
      • Table Depression – Pipeline by NeurOp Inc
      • Table Depression – Pipeline by Newron Pharmaceuticals SpA
      • Table Depression – Pipeline by Nippon Chemiphar Co Ltd
      • Table Depression – Pipeline by nLife Therapeutics SL
      • Table Depression – Pipeline by Omeros Corp
      • Table Depression – Pipeline by Orexigen Therapeutics Inc
      • Table Depression – Pipeline by Otsuka Holdings Co Ltd
      • Table Depression – Pipeline by Pfizer Inc
      • Table Depression – Pipeline by Pherin Pharmaceuticals Inc
      • Table Depression – Pipeline by Polleo Pharma Ltd
      • Table Depression – Pipeline by Protagenic Therapeutics Inc
      • Table Depression – Pipeline by Relmada Therapeutics Inc
      • Table Depression – Pipeline by Reviva Pharmaceuticals Inc
      • Table Depression – Pipeline by Richter Gedeon Nyrt
      • Table Depression – Pipeline by Sage Therapeutics Inc
      • Table Depression – Pipeline by Saniona AB
      • Table Depression – Pipeline by SK Biopharmaceuticals Co Ltd
      • Table Depression – Pipeline by Sound Pharmaceuticals Inc
      • Table Depression – Pipeline by Sumitomo Dainippon Pharma Co Ltd
      • Table Depression – Pipeline by Supernus Pharmaceuticals Inc
      • Table Depression – Pipeline by Suven Life Sciences Ltd
      • Table Depression – Pipeline by Taisho Pharmaceutical Holdings Co Ltd
      • Table Depression – Pipeline by Takeda Pharmaceutical Company Ltd
      • Table Depression – Pipeline by Tetra Discovery Partners LLC
      • Table Depression – Pipeline by Trevena Inc
      • Table Depression – Pipeline by TRImaran Pharma Inc
      • Table Depression – Pipeline by VistaGen Therapeutics Inc
      • Table Depression – Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd
      • Table Depression – Pipeline by Zogenix Inc
      • Table Depression – Pipeline by Zysis Ltd
    • Schizophrenia
      • Table Schizophrenia – Pipeline by Acadia Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Adamed Sp z oo
      • Table Schizophrenia – Pipeline by Aequus Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by AgeneBio Inc
      • Table Schizophrenia – Pipeline by Alkermes Plc
      • Table Schizophrenia – Pipeline by Angita BV
      • Table Schizophrenia – Pipeline by Astellas Pharma Inc
      • Table Schizophrenia – Pipeline by Athersys Inc
      • Table Schizophrenia – Pipeline by Avanir Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Avineuro Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by BCWorld Pharm Co Ltd
      • Table Schizophrenia – Pipeline by BioCrea GmbH
      • Table Schizophrenia – Pipeline by BioHealthonomics Inc
      • Table Schizophrenia – Pipeline by Boehringer Ingelheim GmbH
      • Table Schizophrenia – Pipeline by Braeburn Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Bristol-Myers Squibb Company
      • Table Schizophrenia – Pipeline by Critical Pharmaceuticals Ltd
      • Table Schizophrenia – Pipeline by Curemark LLC
      • Table Schizophrenia – Pipeline by Daewoong Pharmaceutical Co Ltd
      • Table Schizophrenia – Pipeline by Delpor Inc
      • Table Schizophrenia – Pipeline by Denovo Biopharma LLC
      • Table Schizophrenia – Pipeline by Evotec AG
      • Table Schizophrenia – Pipeline by F. Hoffmann-La Roche Ltd
      • Table Schizophrenia – Pipeline by Fabre-Kramer Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Galenea Corp
      • Table Schizophrenia – Pipeline by GeNeuro SA
      • Table Schizophrenia – Pipeline by GlaxoSmithKline Plc
      • Table Schizophrenia – Pipeline by Glenmark Pharmaceuticals Ltd
      • Table Schizophrenia – Pipeline by GP Pharm SA
      • Table Schizophrenia – Pipeline by GW Pharmaceuticals Plc
      • Table Schizophrenia – Pipeline by H. Lundbeck A/S
      • Table Schizophrenia – Pipeline by Heptares Therapeutics Ltd
      • Table Schizophrenia – Pipeline by Hisamitsu Pharmaceutical Co Inc
      • Table Schizophrenia – Pipeline by Indivior Plc
      • Table Schizophrenia – Pipeline by Insys Therapeutics Inc
      • Table Schizophrenia – Pipeline by IntelGenx Corp
      • Table Schizophrenia – Pipeline by Intra-Cellular Therapies Inc
      • Table Schizophrenia – Pipeline by Johnson & Johnson
      • Table Schizophrenia – Pipeline by JT Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Karuna Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by KemPharm Inc
      • Table Schizophrenia – Pipeline by Kowa Company Ltd
      • Table Schizophrenia – Pipeline by Laboratorios Farmaceuticos Rovi SA
      • Table Schizophrenia – Pipeline by Lead Discovery Center GmbH
      • Table Schizophrenia – Pipeline by Lohocla Research Corp
      • Table Schizophrenia – Pipeline by Luye Pharma Group Ltd
      • Table Schizophrenia – Pipeline by Mapi Pharma Ltd
      • Table Schizophrenia – Pipeline by Merck & Co Inc
      • Table Schizophrenia – Pipeline by Mitsubishi Tanabe Pharma Corp
      • Table Schizophrenia – Pipeline by Neurocrine Biosciences Inc
      • Table Schizophrenia – Pipeline by NeurOp Inc
      • Table Schizophrenia – Pipeline by Newron Pharmaceuticals SpA
      • Table Schizophrenia – Pipeline by Omeros Corp
      • Table Schizophrenia – Pipeline by Otsuka Holdings Co Ltd
      • Table Schizophrenia – Pipeline by Peptron Inc
      • Table Schizophrenia – Pipeline by Pfizer Inc
      • Table Schizophrenia – Pipeline by Promentis Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Ra Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Reviva Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Richter Gedeon Nyrt
      • Table Schizophrenia – Pipeline by Sage Therapeutics Inc
      • Table Schizophrenia – Pipeline by SK Biopharmaceuticals Co Ltd
      • Table Schizophrenia – Pipeline by Sumitomo Dainippon Pharma Co Ltd
      • Table Schizophrenia – Pipeline by Sunovion Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Suven Life Sciences Ltd
      • Table Schizophrenia – Pipeline by Taisho Pharmaceutical Holdings Co Ltd
      • Table Schizophrenia – Pipeline by Tetra Discovery Partners LLC
      • Table Schizophrenia – Pipeline by Teva Pharmaceutical Industries Ltd
      • Table Schizophrenia – Pipeline by Vanda Pharmaceuticals Inc
      • Table Schizophrenia – Pipeline by Vitality Biopharma Inc
      • Table Schizophrenia – Pipeline by VLP Therapeutics LLC
      • Table Schizophrenia – Pipeline by Zogenix Inc
      • Table Schizophrenia – Pipeline by Zysis Ltd
    • Tourette Syndrome
      • Table Tourette Syndrome – Pipeline by Abide Therapeutics Inc
      • Table Tourette Syndrome – Pipeline by Catalyst Pharmaceuticals Inc
      • Table Tourette Syndrome – Pipeline by Neurocrine Biosciences Inc
      • Table Tourette Syndrome – Pipeline by Psyadon Pharmaceuticals Inc
      • Table Tourette Syndrome – Pipeline by Reviva Pharmaceuticals Inc
      • Table Tourette Syndrome – Pipeline by Synchroneuron Inc
      • Table Tourette Syndrome – Pipeline by Teva Pharmaceutical Industries Ltd
      • Table Tourette Syndrome – Pipeline by Therapix Biosciences Ltd
  • Dormant Projects
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Dormant Projects
    • Depression
      • Table Depression – Dormant Projects
    • Schizophrenia
      • Table Schizophrenia – Dormant Projects
    • Tourette Syndrome
      • Table Tourette Syndrome – Dormant Projects
  • Discontinued Products
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Attention Deficit Hyperactivity Disorder (ADHD) –Discontinued Products
    • Depression
      • Table Depression – Discontinued Products
    • Schizophrenia
      • Table Schizophrenia – Discontinued Products
    • Tourette Syndrome
      • Table Tourette Syndrome – Discontinued Products
  • Product Development Milestones
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Depression
    • Schizophrenia
    • Tourette Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report